Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy

Shusheng Li

Status: Completed

Conditions: Sepsis-Associated Encephalopathy

Treatments: Drug: ulinastatin

Study type: Observational

Funder types: Other

Identifiers

NCT07090278

SAE-UTI

Details and patient eligibility

About

This study was conducted to explore the association between ulinastatin treatment and the incidence of sepsis-associated encephalopathy (SAE) in patients with sepsis. The study was divided into two phases: first, a multicenter retrospective observational cohort: to evaluate the correlation between ulinastatin treatment and the risk of SAE; second, a single center prospective observational cohort: to further explore the association between ulinastatin treatment and SAE.

Full description

This study consisted of two parts: a retrospective, multicenter observational derivation cohort and a prospective, single-center observational validation cohort. Both parts of the study included adult patients admitted to the intensive care unit of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The first part of the study, being retrospective in nature, was exempted from obtaining informed consent. However, all participants in the second part of the study signed a written informed consent form. The first part of the study retrospectively collected adult patients with sepsis according to the inclusion and exclusion criteria, explored the factors related to sepsis-related encephalopathy, and analyzed the correlation between the use of ulinastatin treatment and the occurrence of SAE. The second part of the study was a prospective study. After signing the informed consent form, eligible patients were included. After collecting blood routine or arterial blood gas analysis, the remaining blood was centrifuged and the plasma was frozen at -80°C for subsequent detection of nitric oxide.

The primary exposure variable was the administration of ulinastatin in patients with sepsis. Demographic data, including age and gender, were collected at ICU admission. Additional exposure variables included blood biochemical markers and infection-related indicators. Clinical comorbidities were recorded based on established diagnoses documented in the medical record, including hypertension, coronary artery disease, atrial fibrillation, diabetes, respiratory diseases (chronic obstructive pulmonary disease, asthma, chronic bronchitis, and bronchiectasis), renal dysfunction, history of tumor, history of stroke, and liver cirrhosis.

The primary outcome was the occurrence of SAE within 3 days of enrollment. Secondary outcomes in the prospective cohort included the fasting blood glucose/ high density lipoprotein cholesterol (FBG/HDL-C), in-hospital mortality, 28-day survival rate, and 28-day survival time.

Enrollment: 2,734 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age ≥18 years
• ICU stay ≥24 hours
• ulfillment of the diagnostic criteria for sepsis according to the Sepsis-3 definition, which included:
• (a) suspected or confirmed infection based on clinical evidence and/or positive microbiological findings;
• (b) Sequential Organ Failure Assessment (SOFA) score ≥2 points

Exclusion criteria

• cognitive impairment related to sedation
• pregnancy
• inability to communicate effectively due to visual, auditory, or language disorders
• primary central nervous system diseases (e.g., cerebrovascular disease, central nervous system infection, autoimmune encephalitis, or epileptic seizures)
• intolerance or allergy to benzodiazepines, or a history of myasthenia gravis, schizophrenia, or severe depressive disorder
• metabolic encephalopathy (including hypoglycemia, diabetic ketoacidosis, hepatic encephalopathy, pulmonary encephalopathy, or uremic encephalopathy)
• poisoning
• skull fracture or intracranial injury

Trial design

2,734 participants in 2 patient groups

Ulinastatin Group

Description:

Patients diagnosed with sepsis who received ulinastatin as part of routine clinical care. The use of ulinastatin was not assigned by study protocol but determined by treating physicians. Clinical outcomes, including the incidence of SAE, were assessed.

Treatment:

Drug: ulinastatin

Non-Ulinastatin Group

Description:

Patients diagnosed with sepsis who did not receive ulinastatin treatment during hospitalization. Clinical outcomes, including the incidence of SAE, were recorded. No study-specific interventions were applied.